TG Therapeutics Inc. (TGTX)
TGTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1001316/000143774926006133/0001437749-26-006133-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TGTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001001316 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $616.3M |
| Net income | $447.2M |
| Operating income | $123.3M |
| Net margin | 72.6% |
| Operating margin | 20.0% |
| Revenue growth | +87.3% |
| Cash | $79.1M |
| Total assets | $1.1B |
| P/E (computed) | 21.2× |
| P/S (computed) | 15.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $429.4M cash; operating cash flow $21.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 151,147,827 (2026-11-04); 158,759,451 a year earlier; 151,410,073 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, New York, New York, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $438K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $259.9M | $55.5M | $45.2M | $429.4M | $745.6M | $897.8M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $240.3M | $7.8M | $39.3M | $482.6M | $745.4M | $799.5M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $204.9M | $19.8M | -$17.9M | $442.2M | $745.1M | $700.3M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $192.6M | $23.0M | $19.7M | $79.1M | $245.6M | $616.3M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $161.7M | $390.9M | -$23.2M | $74.1M | $245.3M | $531.9M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $141.1M | $28.2M | $7.4M | $129.1M | $245.0M | $454.1M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $120.9M | $5.1M | -$28.7M | $132.1M | $244.7M | $386.4M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $108.2M | $23.3M | -$25.6M | $179.9M | $244.4M | $329.0M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3ASR | S-3ASR | 2025-08-08 |
| Latest annual report FORM 10-K | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.8% |
| 1 month | +18.7% |
| 3 months | +34.6% |
| Year to date | +116.4% |
| 1 year | +108.4% |
| From 52-week high | -1.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. Common Stock | $11.82 | -16.47% | $9.5B |
| SYRE | Spyre Therapeutics Inc. | $99.37 | -4.45% | $9.4B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
| PRAX | Praxis Precision Medicines Inc. | $310.27 | -5.44% | $8.7B |
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
| BMRN | BioMarin Pharmaceutical Inc. | $57.99 | +1.33% | $11.2B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier